A recent study finds that the prevalence of post-COVID-19 condition was 8.4 percent among U.S. adults in 2023.

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

COVID-19 infection is not associated with immediate changes in multiple sclerosis symptom severity or disability.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

A recent study finds health care spending in the United States reached $4.9 trillion and increased 7.5 percent in 2023.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...

A new diagnostic test using a dual-biomarker algorithm can inform osteoarthritis diagnosis with high accuracy.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...

Vitamin D3 supplementation was associated with antihypertensive effects without significant between-dose differences among ...